Kodu・Aktsiate loetelu・Edwards Lifesciences Corp

Edwards Lifesciences Corp

Suletud

SektorTervishoid

86.18 -0.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

85.92

Max

86.54

Põhinäitajad
By Trading Economics
Sissetulek	290M 381M
Müük	92M 1.7B
P/E Sektori keskmine	49.429 64.641
Aktsiakasum	0.78
Kasumimarginaal	23.092
Töötajad	16,000
EBITDA	20M 520M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+19.53% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	29. okt 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 48B
Eelmine avamishind	87.13
Eelmine sulgemishind	86.18

Uudiste sentiment

By Acuity

10%

90%

7 / 340 Pingereas Healthcare

Edwards Lifesciences Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. juuli 2026, 19:46 UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

30. juuli 2026, 22:06 UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

29. juuli 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28. juuli 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27. juuli 2026, 19:41 UTC

Social Media

News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24. juuli 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23. juuli 2026, 23:41 UTC

News

Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22. juuli 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21. juuli 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20. juuli 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Võrdlus sarnastega

Hinnamuutus

Edwards Lifesciences Corp Prognoos

Hinnasiht

By TipRanks

19.53% tõus

12 kuu keskmine prognoos

Keskmine 102.88 USD 19.53%

Kõrge 110 USD

Madal 85 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Edwards Lifesciences Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Edwards Lifesciences Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

7 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.